Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin glargine; Drug: NN1250; Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Condition: Multiple Sclerosis
Intervention:
Sponsor: Merck KGaA
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: Matching placebo; Drug: Otelixizumab
Sponsor: GlaxoSmithKline
Not yet recruiting - verified February 2010
Condition: Type 1 Diabetes
Interventions: Other: Closed-loop insulin delivery; Other: Standard insulin pump treatment
Sponsors: University of Cambridge; Cambridge University Hospitals NHS Foundation Trust
Not yet recruiting - verified February 2010
Condition: Diabetes Mellitus, Type 1
Interventions: Drug: NN1250; Drug: insulin detemir (Levemir®); Drug: insulin aspart
Sponsor: Novo Nordisk
Recruiting - verified March 2010
Conditions: Wegener's Granulomatosis; Microscopic Polyangiitis; Churg Strauss Syndrome; Polyarteritis Nodosa; Giant Cell Arteritis; Takayasu Arteritis
Intervention:
Sponsors: University of Oxford; American College of Rheumatology; The European League Against Rheumatism (EULAR); The Vasculitis foundation
Not yet recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Intervention:
Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Not yet recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tociliumab; Drug: methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Drug: ACT-128800; Drug: Placebo
Sponsor: Actelion
Recruiting - verified February 2010
Condition: Juvenile Idiopathic Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: tocilizumab [RoActemra]; Drug: placebo; Drug: NSAIDs, corticosteroids, methotrexate
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Arthritis, Rheumatoid
Interventions: Biological: SC golimumab; Biological: IV golimumab
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: AMG 827 70 mg; Drug: AMG 827 140 mg; Drug: AMG 827 210 mg; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis, Arthritis,
Intervention: Drug: JNJ 38518168 or placebo
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified February 2010
Condition: Type 1 Diabetes Mellitus
Interventions: Drug: Teplizumab (MGA031); Drug: Placebo
Sponsors: MacroGenics; Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Active Rheumatoid Arthritis; Arthritis, Rheumatoid; Rheumatoid Arthritis
Interventions: Drug: etanercept; Drug: methotrexate
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Daclizumab HYP; Drug: Daclizumab HYP
Sponsors: Biogen Idec; Facet Biotech
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: CP 690,550; Drug: CP-690,550; Other: Placebo; Other: Placebo; Biological: Biologic TNFi
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Systemic Sclerosis
Intervention: Drug: treprostinil diethanolamine
Sponsor: United Therapeutics
Not yet recruiting - verified February 2009
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: rituximab [MabThera/Rituxan]; Drug: Placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: methotrexate; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Systemic Sclerosis; Scleroderma
Interventions: Drug: treprostinil diethanolamine; Drug: placebo
Sponsor: United Therapeutics
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: Abatacept
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Rheumatoid Arthritis
Intervention: Drug: tocilizumab [RoActemra]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra]; Drug: Standard anti-rheumatic treatment
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Systemic Lupus Erythematosus
Interventions: Drug: steroids (prednisone or prednisolone) + MMF; Drug: abatacept; Drug: abatacept
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Lupus Nephritis
Interventions: Drug: mycophenolate mofetil [CellCept]; Drug: Cyclophosphamide; Drug: mycophenolate mofetil [CellCept]; Drug: Azathioprine
Sponsors: Hoffmann-La Roche; Aspreva Pharmaceuticals
Recruiting - verified February 2010
Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Drug: eltrombopag olamine (SB-497115-GR)
Sponsor: GlaxoSmithKline
Recruiting - verified February 2010
Conditions: Rheumatoid Arthritis; Osteoarthritis; Post-Traumatic Arthritis; Collagen Disorders; Avascular Necrosis; Traumatic Femoral Fractures; Nonunion of Femoral Fractures; Congenital Hip Dysplasia; Slipped Capital Femoral Epiphysis
Intervention: Device: Pinnacle Acetabular Cup System
Sponsor: DePuy International
Recruiting - verified February 2010